Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details)

Non-Controlling Interests (Schedule of Non-Controlling Interests in Consolidated Entities) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests	$ (32,574)	$ (20,856)	$ (66,292)	$ (38,100)	$ (100,123)
Non-controlling interests in consolidated entities	70,479		70,479		117,203
UR-1 Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			(482)		(1,353)
Non-controlling interests in consolidated entities	$ (664)		$ (664)		$ (1,795)
Non-controlling ownership	34.50%		34.50%		34.50%
Aevitas [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (341)		$ (901)
Non-controlling interests in consolidated entities	$ (5,555)		$ (5,555)		$ (5,060)
Non-controlling ownership	45.90%		45.90%		45.90%
Avenue [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (2,576)		$ (2,909)
Non-controlling interests in consolidated entities	$ 495		$ 495		$ 2,830
Non-controlling ownership	82.80%		82.80%		82.00%
Baergic [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (136)		$ (39)
Non-controlling interests in consolidated entities	$ (2,267)		$ (2,267)		$ (2,086)
Non-controlling ownership	39.00%		39.00%		39.00%
Cellvation [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (110)		$ (131)
Non-controlling interests in consolidated entities	$ (1,691)		$ (1,691)		$ (1,544)
Non-controlling ownership	21.70%		21.70%		21.70%
Checkpoint [Member].
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (25,007)		$ (39,226)
Non-controlling interests in consolidated entities	$ 6,009		$ 6,009		$ 24,238
Non-controlling ownership	80.50%		80.50%		81.50%
Coronado SO [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ 0		$ 0
Non-controlling interests in consolidated entities	$ (290)		$ (290)		$ (290)
Non-controlling ownership	13.00%		13.00%		13.00%
Cyprium [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (421)		$ (807)
Non-controlling interests in consolidated entities	$ (2,803)		$ (2,803)		$ (2,204)
Non-controlling ownership	29.00%		29.00%		29.80%
Helocyte [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (184)		$ (89)
Non-controlling interests in consolidated entities	$ (5,655)		$ (5,655)		$ (5,529)
Non-controlling ownership	17.90%		17.90%		18.30%
JMC [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (3,302)		$ (5,652)
Non-controlling interests in consolidated entities	$ 17,723		$ 17,723		$ 17,498
Non-controlling ownership	50.90%		50.90%		41.60%
Mustang [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (33,580)		$ (48,518)
Non-controlling interests in consolidated entities	$ 67,212		$ 67,212		$ 93,009
Non-controlling ownership	82.00%		82.00%		82.70%
Oncogenuity [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (139)		$ (497)
Non-controlling interests in consolidated entities	$ (1,277)		$ (1,277)		$ (1,124)
Non-controlling ownership	24.50%		24.50%		24.90%
Tamid [Member]
Noncontrolling Interest [Line Items]
Net loss attributable to non-controlling interests			$ (14)		$ (1)
Non-controlling interests in consolidated entities	$ (758)		$ (758)		$ (740)
Non-controlling ownership	22.80%		22.80%		22.80%